Mycenax Biotech (4726.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Taiwan · ISIN TW0004726005

Price
22.20 TWD
Market cap
4.60 bn TWD
P/E (2025)
–
P/S (2025)
6.21
Dividend yield
0.00 %
Net margin
-60.61 %
Return on equity (ROE)
-28.06 %
Return on assets (ROA)
-13.76 %

Mycenax Biotech financials

Fiscal year20242025
Revenue683.92 m TWD740.24 m TWD
Gross profit-241.36 m TWD-181.41 m TWD
Operating income-461.48 m TWD-405.39 m TWD
EBIT-439.67 m TWD-420.44 m TWD
Net income-467.13 m TWD-448.63 m TWD
Diluted EPS – continuing operations-2.26 TWD-2.16 TWD

Full history since 2017, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Mycenax Biotech

Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers CDMO services, including integrated biologics development services, specialized modalities, manufacturing, and quality services. It also offers bispecific antibody production, and NaxLeap, a transposon system; PlasMX, a plasmid DNA manufacturing; differential scanning fluorimetry; antibody-drug conjugates; cell and gene therapy, including allogeneic immune cell solutions, and ExoMX, a exosome manufacturing; and white papers, articles, and posters and flyers. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.